Medical Ikkou Group Co., Ltd. (3353) AI Stock Analysis

• Market Cap: ¥9.89B
• Dividend Yield: 3.51%
• Average Volume (3M): 5.09K
• Price to Earnings (P/E): 9.9
• Beta (1Y): 0.43
• Revenue Growth: 16.73%
• EPS Growth: -16.51%
• Country: JP
• Employees: 1,431
• Sector: Industrials
• Sector Strength: 72
• Industry: Conglomerates
• EPS (TTM): 60.74
• Shares Outstanding: 3,770,000
• 10 Day Avg. Volume: 10,430
• 30 Day Avg. Volume: 5,086
• PEG Ratio: 0.82
• Price to Book (P/B): 0.59
• Price to Sales (P/S): 0.17
• P/FCF Ratio: 41.09
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 67 Neutral
• Price Target: ¥3,125.00 ▲(9.50% Upside)

The overall stock score is primarily driven by strong financial performance, particularly in revenue growth and operational efficiency. However, technical indicators suggest bearish momentum, which could pose short-term risks. The stock's valuation appears attractive with a low P/E ratio and a solid dividend yield, offering potential value for long-term investors.

Positive Factors

Revenue Growth

The company's robust revenue growth indicates strong demand for its products and services, enhancing its market position and supporting long-term business expansion.

Operational Efficiency

Improved operational efficiency through better cost management enhances profitability and competitiveness, contributing to sustainable growth.

Balance Sheet Health

A strong equity ratio indicates financial stability and the ability to withstand economic fluctuations, supporting long-term strategic initiatives.

Negative Factors

Cash Flow Challenges

Significant reduction in operating cash flow can limit the company's ability to invest in growth opportunities and manage financial obligations effectively.

Net Profitability

Stagnant net profit margins indicate challenges in translating revenue growth into bottom-line improvements, potentially affecting long-term profitability.

Debt Levels

High debt levels may constrain financial flexibility and increase vulnerability to interest rate changes, impacting long-term financial health.

Medical Ikkou Group Co., Ltd. Business Overview & Revenue Model

Company Description

Medical Ikkou Group Co., Ltd. (3353) is a Japan-based company specializing in the healthcare sector, primarily focusing on the development and provision of medical devices and services. The company is involved in various aspects of the medical field, including diagnostics, treatment solutions, and healthcare management systems. Its core products encompass advanced medical technologies aimed at enhancing patient care and operational efficiency within healthcare facilities.

How the Company Makes Money

Medical Ikkou Group generates revenue through multiple key streams, including the sale of medical devices and equipment to hospitals and clinics, as well as providing maintenance and support services for their products. The company may also derive income from partnerships with healthcare providers and institutions for the deployment of its technologies in clinical settings. Additionally, revenue can come from research and development collaborations, licensing agreements, and potential government contracts aimed at improving public health initiatives. The company's focus on innovation and quality products enables it to establish long-term relationships with clients, thereby driving consistent revenue growth.

Medical Ikkou Group Co., Ltd. Financial Statement Overview

Summary

Medical Ikkou Group Co., Ltd. demonstrates strong revenue growth and operational efficiency, but faces challenges in net profitability and cash flow management. The balance sheet reflects stability with a healthy equity ratio and manageable debt levels. While the income statement shows a positive growth trajectory, cash flow constraints could impact future financial flexibility.

Income Statement

Medical Ikkou Group Co., Ltd. has shown strong revenue growth with a 21.3% increase from 2024 to 2025. The gross profit margin has improved to 11.6% in 2025 from 11.4% in 2024, indicating better cost management. The EBIT margin also improved to 3.5% in 2025 from 3.9% in 2024, showcasing operational efficiency. However, the net profit margin remained stable at around 2.3%, suggesting room for improvement in net profitability.

Balance Sheet

The company maintains a healthy equity ratio of 41.2% in 2025, reflecting strong solvency. The debt-to-equity ratio decreased to 0.71 in 2025 from 0.72 in 2024, showing effective debt management. ROE was stable at 8.0% in 2025, indicating consistent return on shareholders' equity. However, the total debt level remains significant, which could pose a risk if not managed properly.

Cash Flow

Operating cash flow decreased significantly to ¥1.2 billion in 2025 from ¥4.3 billion in 2024, negatively impacting free cash flow, which dropped by 94.9%. The free cash flow to net income ratio declined, signaling potential cash flow issues relative to earnings. However, the company generated positive free cash flow, indicating some level of operational efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	52.66B	48.39B	39.90B	33.90B	33.60B	31.60B
Gross Profit	6.11B	5.61B	4.55B	3.18B	3.61B	3.20B
EBITDA	2.26B	2.73B	2.50B	2.21B	2.41B	2.33B
Net Income	1.09B	1.13B	1.04B	759.60M	852.33M	834.99M
Balance Sheet
Total Assets	37.91B	34.23B	31.66B	27.51B	29.09B	28.55B
Cash, Cash Equivalents and Short-Term Investments	8.60B	6.77B	7.70B	6.44B	7.99B	7.00B
Total Debt	11.43B	10.02B	9.58B	9.12B	11.31B	11.85B
Total Liabilities	22.64B	19.52B	17.82B	14.90B	17.17B	18.07B
Stockholders Equity	14.64B	14.10B	13.24B	12.05B	11.38B	10.48B
Cash Flow
Free Cash Flow	0.00	201.34M	3.95B	960.14M	798.00M	1.33B
Operating Cash Flow	0.00	1.20B	4.28B	1.31B	1.14B	1.82B
Investing Cash Flow	0.00	-1.13B	-3.22B	-477.52M	-215.52M	-1.18B
Financing Cash Flow	0.00	-1.03B	277.76M	-2.37B	64.74M	590.88M

Medical Ikkou Group Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2854.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3353, the sentiment is Positive. The current price of 2854 is above the 20-day moving average (MA) of 2692.00, above the 50-day MA of 2711.02, and above the 200-day MA of 2663.64, indicating a bullish trend. The MACD of 21.80 indicates Negative momentum. The RSI at 68.59 is Neutral, neither overbought nor oversold. The STOCH value of 84.08 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3353.

Medical Ikkou Group Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7795	73 Outperform	¥9.22B	7.76	―	3.79%	6.83%	41.94%
7670	71 Outperform	¥10.91B	6.08	―	4.15%	-5.07%	13.98%
6554	69 Neutral	¥10.30B	11.04	―	3.90%	13.59%	52.99%
3353	67 Neutral	¥9.89B	9.87	―	3.51%	16.73%	-16.51%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
7490	62 Neutral	¥7.78B	24.69	―	2.23%	3.47%	1062.58%
7066	60 Neutral	¥4.42B	9.37	―	3.64%	-1.69%	-18.95%